Inventors of the Immune Refocusing Technology, a method for the rational design of antigens. In 2018, Goldman Sachs analysts predicted that genomic medicine will grow to a $5 Trillion (annual) industry (see video).
“It was this approach that made it possible to deliver 75,000 sq feet of functional space in a record-worthy 15 months after kick-off, helping to put the company in a position to confidently bring on new client programs and grow their pipeline.” shared Matt Khair, CRB’s Senior Associate at the grand opening event for Paragon’s new facility.
Two gene therapy candidates on ARM’s list are not included. Johns Hopkins and the University of Maryland are not only leading research centers but they are spinning out multiple companies each year to move their discoveries to the bedside. Biotech develops novel biologics for the treatment of cancer, autoimmune disease, infectious diseases. Focused on curing humanity's ailments through stem cell biology. Developed in the Demirci Bio-Acoustic MEMS in Medicine Labs. Developing a novel technology platform with broad application across multiple disease areas. Biotech operates in the synthetic biology field, designs, builds and regulates gene programs. More than a third of ex vivo modified gene therapy clinical trials use a lentiviral delivery method, and more than 100 clinical trials have now conducted or are in progress using lentiviral vectors, with significant success in LV-modified CAR-T cells and also LV-modified stem cells. Clinical-stage biopharma, focused on the acquisition, development of drug candidates for global markets with a focus on China. In fact, this year, Rockville, Maryland’s gene therapy company REGENXBIO (RGNX) received its first FDA approval for ZOLGENSMA which was created as a one-time fix for spinal muscular atrophy in toddlers under the age of two (press release). Integrated Discrete Multiple Organ Culture plate (IdMOC) provides a method to model in vivo multiple-organ interaction in vitro.
Somerset-based drug delivery company Catalent has invested $130 million to bolster manufacturing capacity at its gene therapy campus in Maryland, it announced Wednesday. Once these cells are equipped to find and eliminate the cancer, they are replicated and infused back into the same patient. These are rare but utterly devastating diseases, resulting in severe motor capabilities and … There are 30 gene-therapy development companies in the Philadelphia area that have raised well over $1 billion in invested capital, and together employ more than 3,000 people. © 2020 The Philadelphia Inquirer, LLC Terms of Use/Privacy Policy, Food and Drug Administration approvals for commercial applications, $50 million of university funds in faculty companies. Discovers develops personalized medicine products that improve screening, monitoring, and targeted treatment of cancer and human diseases. Its HIV Cure Technology uses modified T-Cells made from a person’s own cells to disable the disease and build immunity to the virus. The current manufacturing method has been simplified from earlier generations of AAV vectors, and is now less likely to trigger an immune response in the recipient. Biotech specialized in (I)immune-based long-acting protein drugs. Focused on developing a new class of biotherapeutics that address the complexity of diseases by simultaneously targeting multiple biological pathways. Uses functional human tissue to predict drug activity prior to clinical trials. The methodology promotes iterative design, engineering and construction throughout the life-cycle of the project, close collaboration between the design and construction teams, subcontractors and client-side, constant communication, and tightly-knit teams focused on a single goal – delivering exceptional results for the client.
Research and Development Group focuses on producing intellectual property and recombinant. Lab Owl™, operating out of Rockville, Maryland, provides a fully customizable and scalable platform for bioreactor controls. Offers genomics, proteomics, and glycomics solutions. However, unlike other states, Maryland contains the highest per capita of PhDs.
Develops NexGen life science research reagents to support drug discovery and functional genomics with a focus on viral vector-based gene delivery. Develops a therapeutic technology to convert a patient's cells as a treatment for diabetes. Manufactures and markets molecular and immunological products and services to the bioscience research community. Catalent Gene Therapy in Catonsville, MD is located within the UMBC Research & Technology Park, adjacent to the UMBC campus.
To put that in perspective, the total revenue of the current global pharmaceutical market is just a little over $1 Trillion today (Deloitte 2018 Global Life Sciences Outlook).